TwinBeech Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

TwinBeech Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-6,428	Closed	-$1.36M	–	805
2024 Q3	$1.36M	Buy	+6,428	New	+$1.64M	0.03%	462
2023 Q2	–	Sell	-13,016	Closed	-$3.15M	–	763
2023 Q1	$3.15M	Buy	+13,016	New	+$3.55M	0.06%	312
2021 Q3	–	Sell	-2,188	Closed	-$213K	–	691
2021 Q2	$213K	Buy	+2,188	New	+$259K	0.03%	412
2020 Q1	–	Sell	-2,199	Closed	-$200K	–	402
2019 Q4	$200K	Buy	+2,199	New	+$213K	0.06%	360

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TwinBeech Capital's MDGL Position: Q4 2024 in Review

TwinBeech Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2024, closing a stake of 6,428 shares — an estimated $1.36M sold.

TwinBeech Capital first reported a position in MDGL in Q4 2019 and held it in 4 quarters. The position peaked at $3.15M in Q1 2023. 283 funds tracked by Wall St. Rank hold MDGL as of Q4 2024.

TwinBeech Capital reported no remaining Madrigal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
TwinBeech Capital sold 6,428 Madrigal Pharmaceuticals shares in Q4 2024, an estimated $1.36M.
TwinBeech Capital first reported a position in Madrigal Pharmaceuticals in Q4 2019 and held it in 4 quarters.
TwinBeech Capital's Madrigal Pharmaceuticals position peaked at $3.15M in Q1 2023.
283 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2024.

Based on TwinBeech Capital's 13F filing for Q4 2024, filed 14 Feb 2025.